Related Experiment Video
Updated: Jun 18, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Folate in depression: efficacy, safety, differences in formulations, and clinical issues
Maurizio Fava1, David Mischoulon
1Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 351, Boston, MA 02114, USA. mfava@partners.org
The Journal of Clinical Psychiatry
|November 14, 2009
Summary
Folate supplementation may alleviate depressive symptoms by aiding neurotransmitter synthesis. Different folate forms, like 5-methyltetrahydrofolate, show promise in treating depression, dementia, and alcoholism, though more research is needed.
Area of Science:
- Nutritional Neuroscience
- Psychiatry
- Pharmacology
Background:
- Folate, a B vitamin, is crucial for brain neurotransmitter synthesis (norepinephrine, serotonin, dopamine).
- Depression is linked to folate metabolism, with various forms of folate used therapeutically.
- Bioavailability of folate forms can vary based on genetics, medications, and alcohol use.
Purpose of the Study:
- To review the efficacy and safety of folate supplementation for reducing depressive symptoms.
- To explore the effectiveness of different folate forms (folic acid, 5-MTHF, folinic acid) in various patient populations.
- To assess folate's impact on cognitive function and its potential risks.
Main Methods:
- Systematic review of studies on folate supplementation and depressive symptoms.
- Analysis of data concerning different folate formulations and their therapeutic applications.
- Evaluation of evidence regarding folate's effects on cognitive function and safety concerns.
Main Results:
- Folic acid augmentation may reduce residual depressive symptoms.
- 5-Methyltetrahydrofolate (5-MTHF) demonstrated efficacy as monotherapy or adjunctive therapy for depression, dementia, and alcoholism.
- Folinic acid showed benefit as adjunctive therapy in patients unresponsive to SSRIs.
- Evidence for folate improving cognitive symptoms is inconclusive, with most studies using folic acid.
Conclusions:
- Several folate forms appear safe and effective for some individuals with major depressive disorder.
- 5-MTHF may offer advantages over folic acid regarding bioavailability and potential risks.
- Further research is required to determine optimal dosages and patient populations for folate therapy.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:18Depression: Overview
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...